A Micro-Costing Framework for Circulating Tumor DNA testing In Dutch Clinical Practice.

Circulating tumor DNA (ctDNA) is a promising new biomarker with multiple potential applications in cancer care. Estimating total cost of ctDNA-testing is necessary for reimbursement and implementation, but challenging due to variations in workflow. We aimed to develop a micro-costing framework for consistent cost calculation of ctDNA-testing. First, the foundation of the framework was built, based on the complete step-wise diagnostic workflow of ctDNA-testing. Second, the costing method was set-up, including costs for personnel, materials, equipment, overhead, housing, and failures.

Source: Journal of Molecular Diagnostics - November 16, 2022 Category: Pathology Authors: Astrid Kramer, Ed Schuuring, Daan C.L. Vessies, Paul van der Leest, Maartje J. Geerlings, Pim Rozendal, Mirthe Lanfermeijer, Theodora C. Linders, L éon C. van Kempen, Remond J.A. Fijneman, Marjolijn J.L. Ligtenberg, Gerrit A. Meijer, Daan van den Broek, Tags: Regular Article Source Type: research